LGND
Ligand Pharmaceuticals Incorporated
Biotechnology · Healthcare · United States
317.33
close · 2026-10-29
value
20
cheaper than peers20
quality
73
stronger fundamentals73
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 21.77× | 38 |
| forward P/E | 26.54× | 32 |
| price to book | 6.53× | 30 |
| EV to EBITDA | 46.08× | 20 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 22.0% | 89 |
| operating margin | 13.5% | 83 |
| revenue growth | 33.7% | 58 |
| debt to equity | 116.9% | 20 |
4 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | $139.7M |
| employees | 47 |
| first trade | 1992-11-18 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 6.13 | -0.22 | 2.94 | -1.98 |
| free cash flow | $38.0M | $77.4M | -$4.3M | $119.9M |
| net income | $124.5M | -$4.0M | $52.2M | -$33.4M |
| revenue | $268.1M | $167.1M | $131.3M | $196.2M |
| unusual items | $102.9M | -$5.2M | $48.5M | $28.5M |